Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252313004 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Viacheslav Varachev und 12 weiteren Autor:innen. Beteiligte Einrichtung: Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Glioma, Biomarkers, Tumor, Brain Neoplasms, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Russian Science Foundation, Russian Science Foundation.
Abstract (Originalsprache)
Gliomas are a heterogeneous group of brain tumors, among which the most aggressive subtype is glioblastoma, accounting for 60% of cases in adults. Available systemic treatment options are few and ineffective, so new approaches to therapies for glioblastoma are in high demand. In total, 131 patients with diffuse glioma were studied. Paired tumor–normal samples were sequenced on the Illumina platform; the panel included 812 genes associated with cancer development. Molecular profiles in clinically distinct groups were investigated. In low-grade glioma (LGG) patients (n = 18), the most common mutations were IDH1/2 (78%), ATRX (33%), TP53 (33%), PIK3CA (17%), and co-deletion 1p/19q (22%). In high-grade glioma (HGG) patients (n = 113), more frequently affected genes were CDKN2A/B (33%), TERTp (71%), PTEN (60%), TP53 (27%), and EGFR (40%). The independent predictors of better prognosis were tumor grade and IDH1/2 mutations. In IDH—wildtype glioblastoma patients, a history of other precedent cancer was associated with worse overall survival (OS), while re-operation and bevacizumab therapy increased OS. Also, among genetic alterations, TERTp mutation and PTEN deletion were markers of poor prognosis. Nine patients received molecular targeted therapy, and the results were evaluated. The search for molecular changes associated with tumor growth and progression is important for diagnosis and choice of therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
- N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.
- I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
ORCID-Profile: Viacheslav Varachev, George Krasnov, Anna Ikonnikova, Svetlana Bezhanova, Evgenii Prozorenko, Yulia Ammour, Tatiana Nasedkina
Förderung
- the Russian Science Foundation
- Russian Science Foundation
Zitieren
APA
Varachev, V., Susova, O., Mitrofanov, A., Naskhletashvili, D., Krasnov, G., Ikonnikova, A., Bezhanova, S., Semenova, V., Sevyan, N., Prozorenko, E., Ammour, Y., Bekyashev, A., & Nasedkina, T. (2024). Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252313004
Vancouver
Varachev V, Susova O, Mitrofanov A, Naskhletashvili D, Krasnov G, Ikonnikova A, et al. Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252313004
BibTeX
@article{Varachev2024,
author = {Varachev, Viacheslav and Susova, Olga and Mitrofanov, Alexei and Naskhletashvili, David and Krasnov, George and Ikonnikova, Anna and Bezhanova, Svetlana and Semenova, Vera and Sevyan, Nadezhda and Prozorenko, Evgenii and Ammour, Yulia and Bekyashev, Ali and Nasedkina, Tatiana},
title = {Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252313004}
}
EUVIMED